Gemeinschaftspraxis fuer Neurologie Dr. med. W. Blersch und Dr. med. J. Redelstein
- Address
- Guenzstrasse 1, 93059 Regensburg, Germany
Nervous System Diseases
The practice concentrates on progressive multiple sclerosis, exploring ways to improve outcomes for patients with advanced disease.
- Primary Progressive Multiple Sclerosis (PPMS)
- Non‑active Secondary Progressive Multiple Sclerosis (naSPMS)
The trials test the oral orelabrutinib against placebo. Researchers aim to slow disability progression in these forms of MS at the Gemeinschaftspraxis für Neurologie in Regensburg, Germany.
Site Overview
Activity Indicator
Last 6 months
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Zenas Biopharma (USA) LLC2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Zenas Biopharma (USA) LLC2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis fuer Neurologie Dr. med. W. Blersch und Dr. med. J. Redelstein
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized Double-Blind Study of Orelabrutinib for Primary Progressive Multiple Sclerosis in Patients With PPMS | Zenas Biopharma (USA) LLC | Phase III | Recruiting | Jun 2026 | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.